To our knowledge, there is only a phase 1 clinical trial testing a humanized anti-CD40 antibody administered systemically for pediatric central nervous system tumors, including newly diagnosed DIPG (NCT03389802). The gene discussed is CD40; the disease is central nervous system cancer.